drugset
drugset / Trial / NCT01858558

Tadalafil and Lenalidomide Maintenance With or Without Activated Marrow Infiltrating Lymphocytes (MILs) in High Risk Myeloma

NCT01858558 ↗

Phase 2 Completed 102 enrolled Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins The Leukemia and Lymphoma Society · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

This research is being done to find out if altering the immune system by giving activated marrow infiltrating lymphocytes (MILs) can improve outcomes for multiple myeloma patients who receive a standard autologous stem cell transplant.

Timeline

Start
2013-09
Primary completion
2019-06-19
Completion
2019-06-19

Drugs

EvaluationDrugModalityDoseRoute
Subject aMIL Unknown — —

Indications

plasma cell myeloma